A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab

A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab

Abstract Background Anti-CTLA-4 immune checkpoint blockade is associated with immune-related adverse events (irAEs). Grade 3–4 diarrhea/colitis is the most frequent irAE requiring treatment discontinuation. Predicting high-risk diarrhea/colitis patients may facilitate early intervention, limit irAE...

Full description

Bibliographic Details
Main Authors: Philip Friedlander, Kevin Wood, Karl Wassmann, Alan M. Christenfeld, Nina Bhardwaj, William K. Oh
Format: Article
Language:English
Published: BMJ Publishing Group 2018-09-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Melanoma
Immunotherapy
irAE
Biomarker
CTLA-4
Diarrhea
Online Access:http://link.springer.com/article/10.1186/s40425-018-0408-9

Similar Items

Similar Items